Krsnaa Diagnostics Limited

rs,

T'S DO GOOD ' Date: 28th May, 2023 BSE Ltd. Corporate Service Department ist Floor, P.J. Towers, Dalal Street, Mumbai 400 001 Scrip ID: KRSNAA Scrip Code: 543328 Dear Sir/Madam, Subject: FY

Rs. 487

nostic Service Provider FY2023 and Q4 Performance 2 Krsnaa Diagnostics Financial- At a Glance Rs. 487 cr FY23 Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT M

Rs. 124

FY2023 and Q4 Performance 2 Krsnaa Diagnostics Financial- At a Glance Rs. 487 cr FY23 Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share

25%

4 Performance 2 Krsnaa Diagnostics Financial- At a Glance Rs. 487 cr FY23 Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55%

Rs. 62

s Financial- At a Glance Rs. 487 cr FY23 Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35%

13%

At a Glance Rs. 487 cr FY23 Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35% Revenue

Rs. 2.75

Revenue Rs. 124 cr | 25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36

55%

25% FY23 EBITDA* and EBITDA Margin Rs. 62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36% Radiology Rev

35%

62 cr | 13% FY23 PAT and PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36% Radiology Revenue 5Y CAGR 66% PAT 5Y CAGR 33% Path

34%

nd PAT Margin Rs. 2.75 per share | 55% on Face Value FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36% Radiology Revenue 5Y CAGR 66% PAT 5Y CAGR 33% Pathology Revenue 5Y CAG

36%

5 per share | 55% on Face Value FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36% Radiology Revenue 5Y CAGR 66% PAT 5Y CAGR 33% Pathology Revenue 5Y CAGR A (Stable) ICRA Ra

66%

FY23 Final Dividend 35% Revenue 5Y CAGR 34% EBITDA* 5Y CAGR 36% Radiology Revenue 5Y CAGR 66% PAT 5Y CAGR 33% Pathology Revenue 5Y CAGR A (Stable) ICRA Rating 100% Technical Bid Win Rat

“As we move forward, we anticipate further enhancement in our margins as our recently launched centers reach maturity.”

“Maturity is on the basis of the project start date 3.”

“37 Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation ₹ Total Centre count increased at a CAGR of 33% from 682 in FY18 to 2,800+ in FY23 Centres across India with presence in 17 States and Union Territories.”

Notes

3

Note

1

For further information please contact

1

Notes

* EBITDA is excluding CSR and ESOP expenses Last 5 Years CAGR is for the period FY2018-23 3 Krsnaa Diagnostics Operations- At a Glance 1,528 Tele-reporting Centres 133 CT/MRI Centres 99 Pathology Processing Lab 1,090 Pathology Collection Centres 220+ Doctors 2,850 Total Centres and Labs 120+ District Locations 17+ States & Union Territory 31 Mn+ Patients Served Last 5 Years 10 Mn+ Patients Served FY23 33% Total Centre Count CAGR 5Y (FY18- 23) 42 Krsnaa Business Associates 15 NABH accredited centres 16 NABL accredited centres India’s 1st NABH Accredited Teleradiology HUB in 2023 4 Tenders won in the last 12 Months - Strong pipeline for growth in a competitive market Jun 2022 Jul 2022 Jan 2023 Feb 2023 Apr 2023 Tripura X-Ray Tele- Reporting Contract Provides X-Ray Tele-Radiology services across all districts of Tripura Rajasthan Radiology Contract To deploy 1 CT Scan Machine at MES Medical College at Churu, a City in Rajasthan Bombay Municipal Cooperation Pathology Contract Established 6

Notes

1. Covid-19 Business is including Covid allied tests 2. 3. EBITDA is excluding CSR and ESOP expense EBIT including Other Income 16 Balance Sheet Assets (In Million) FY22 FY23 Equity and Liabilities (In Million) FY22 FY23 Non-Current Assets Property, plant and equipment Capital work-in-progress Intangible assets Intangible asset under development Financial assets Investments Loans Other financial assets Deferred tax asset (net) Other non-current assets Current Assets Inventories Financial assets Trade receivables Cash and cash equivalents Bank balances other than cash and cash equivalent Other financial assets Other current assets Total Assets 5,420.06 6,841.31 3,833.79 4,678.47 282.57 23.15 - 254.80 28.28 - 2.91 - 2.91 - 1,155.15 1,711.16 7.88 114.61 13.88 151.81 3,341.47 2,257.62 91.70 250.74 578.73 884.53 1,534.28 118.56 133.67 730.97 227.20 860.76 117.96 69.99 Total Equity Equity share capital Instruments entirely equity in nature Other equity Non-Current Liabilities Borrowings Leas

Notes

1. 2. Maturity is on the basis of the project start date 3. Return on Capital Employed calculated as (EBIT including Other Income / Gross Block) 31 B2C Pathology Strategy for FY2024 Expanding test menus by adding more specialized tests at disruptive prices Core strategy is to set up and operationalize Home Collection Hub and Preventive Health check up promotion in Two Phases Molecular Diagnostics Flow Cytometry Histopathology & IHC Markers Genetics (NGS) Digital Pathology & AI Specialised Test 4 Growth Strategy Phase I – Maharashtra, Punjab Phase II – Odisha, Assam, Rajasthan 32 Best-in-class infrastructure and services at disruptive rates – high brand recall leading to increased foot-falls High quality infrastructure and services at disruptive prices creates market awareness and drives direct walk-ins 4 Growth Strategy 33 Retail Market Expansion Strategy Leveraging Digital Initiatives R&A – Customer Review Social Media Customer Call Centre Hub Dedicated Website Customer Engagement Str

Note

1. 2. Mr. Adesh Kumar Gupta has been appointed as an Independent Director w.e.f 28th May, 2022 Leadership Team members, Rajendra Mutha is the Executive Director and Chairman, Pallavi Bhatevara is the Executive Director and Managing Director, Yash Mutha is the Executive Director. 37 Krsnaa Diagnostics Edge One of the Fastest Growing Diagnostics Service Provider in the country Extensive Geographic Footprint Strong Brand Equity Scalable and Agile Business Model Disruptive Pricing Stakeholder Value Creation ₹ Total Centre count increased at a CAGR of 33% from 682 in FY18 to 2,800+ in FY23 Centres across India with presence in 17 States and Union Territories. Diagnostic equipment is state-of-the-art and procured from leading OEMs Well positioned to partner with the Government’s initiative to provide equitable, affordable and quality health care services PPP is an asset light model which ensures robust revenue and long-term contract provides revenue visibility Ability to maintain cost compet

For further information please contact

Krsnaa Diagnostics Vipin Dayma, Secretarial Team cs@krsnadiagnostics.com Contact: +91 20 4695 4695 Churchgate Partners Anvita Raghuram / Rajiv Pandya krsnaa@churchgatepartners.com Contact: +91 22 6169 5988 41